Entrada Therapeutics Q2 collaboration revenue drops, net loss widens

Entrada Therapeutics

06/08/2025 12:11

Overview

Entrada Therapeutics Q2 net loss of $43.1 mln vs. net income last yr

Collaboration revenue drops sharply to $2 mln from $94.7 mln last yr

Cash position at $354 mln, sufficient to fund operations into Q2 2027

Outlook

Company expects cash runway to last into Q2 2027

Entrada anticipates reporting ELEVATE-44-201 data in H1 2026

Company plans regulatory submission for ENTR-601-50 in Q4 2025

Entrada expects ELEVATE-45-201 data readout in mid-2026

Result Drivers

CLINICAL TRIAL PROGRESS - First patient dosed in ELEVATE-44-201 and multiple sites activated for ELEVATE-45-201

R&D EXPENSES - Increased costs due to advancement of Duchenne muscular dystrophy programs

COLLABORATION REVENUE DROP - Sharp decline in revenue attributed to completion of Vertex collaboration activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
$1.95 mln
Q2 EPS
-$1.04
Q2 Net Income
-$43.10 mln
Q2 Income From Operations
-$46.85 mln
Q2 Operating Expenses
$48.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Entrada Therapeutics Inc is $20.50, about 71.6% above its August 5 closing price of $5.83

Press Release: ID:nGNX4wSqw

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)